For a decade Jim Tobin has been at the helm of Boston Scientific (Natick, Massachusetts). Throughout his tenure, he's faced unique situations and challenges, such as the med-tech industry's meteoric rise following the bursting of the dot.com bubble, and Boston Sci's highly controversial commitment of $27 billion to buy Guidant (Indianapolis). (Medical Device Daily)

Initial results from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) are proving to be more than just a shining endorsement for the use of these applications. In the few days since the report came out, companies occupying the market space for CRT-D devices have seen significant gains in their stock prices. (Medical Device Daily)

With a drug-eluting stent that promises more flexibility and safer outcomes after use, Abbott (Abbott Park, Illinois) plans to continue pushing past its competitors in the DES market. The company took a few steps and made further movements toward this goal yesterday, when it reported receiving the CE mark for its Xience Prime DES. (Medical Device Daily)

The continued shortage of medical isotopes could bring back more invasive and expensive imaging techniques in the diagnosis of patients, according to speakers during a press conference held by the Society of Nuclear Medicine (Reston, Virginia) during its annual meeting. (Diagnostics & Imaging Week)

Device and pharmaceutical makers who market products in the Commonwealth of Massachusetts are going to face an even greater degree of scrutiny when it comes to reporting gifts and contributions to physicians starting July 1. (Medical Device Daily)